ClinicalTrials.gg
CompletedNCT05360784Updated Aug 26, 2024Results posted

"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"

A Phase 3 interventional study of Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation and Lumify® (brimonidine tartrate ophthalmic solution 0.025%) in Ocular Redness, sponsored by Bausch & Lomb Incorporated. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-26.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multi-center, double-masked, randomized, active-controlled, parallel-group, efficacy and safety study that will enroll 386 participants at up to six clinical sites. Participants with ocular redness will be randomized to receive either brimonidine tartrate ophthalmic solution 0.025%, preservative-free formulation, or Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will be treated with study drug for approximately 4 weeks.

02

Conditions studied

  • Ocular Redness
03

In context

Lead sponsor

Bausch & Lomb Incorporated is the lead sponsor of 223 studies on the registry; 5 are open to participants now.

Of its 51 completed or terminated interventional studies of FDA-regulated products, 41 (80%) have results posted.

First submitted after Bausch & Lomb Incorporated became part of Bausch Health Companies Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be at least 18 years of age at the time of signing of either gender and any race or ethnicity;
  2. Provide written informed consent and sign the HIPAA form;
  3. Be willing and able to follow all instructions and attend all study visits;
  4. Have a history of vasoconstrictor (redness relief drops) use within the last 6 months, or a desire to use OTC vasoconstrictors for redness relief;
  5. Be able to self-administer eye drops satisfactorily or have a subject's care provider at home1 routinely available for this purpose;
  6. (If female and of ) agree to have urine pregnancy testing performed at Visit 1 (must be negative) and at exit visit; must not be lactating; and must agree to use at least 1 medically acceptable form of birth control2 throughout the study duration and for at least 14 days prior to the first dose of study drug (Visit 1) and for 1 month after the last dose of drug. Note: Women considered capable of becoming pregnant include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) and have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy);
  7. (If male and with female partner of childbearing potential) must use at least 1 medically acceptable form of birth control3;
  8. A calculated best-corrected (if necessary) visual acuity of 0.3 logMAR or better in each eye, as measured using an ETDRS chart;
  9. At Visit 1 (Baseline), show a baseline redness score >1 unit (ie, greater than 1 unit) in both eyes on a 0 to 4 unit scale as scored by the Investigator using the Investigator Ocular Redness Scale;
  10. Have stable ocular health (defined as no ocular conditions requiring therapy or surgical intervention during the study).

Exclusion criteria

Exclusion Criteria:

  1. Have known or sensitivity to the use of any of the drug(s) or their components, or any other medications required by the protocol;
  2. Have had ocular surgical intervention within 3 months prior to screening or during the study and/or a history of refractive surgery within the past 6 months;
  3. Have the presence of an active ocular infection (bacterial, viral, or fungal) or positive history of an ocular herpetic infection at any visit;
  4. Use any of the following disallowed medications during the period indicated prior to screening and for the duration of the study:

    • All topical ophthalmic agents including artificial tear products, eye whiteners (e.g., vasoconstrictors), ocular decongestants, ocular antihistamines, ocular , dilating drops, (excluding dilated ophthalmoscopy exam at Visit 1) and contact lenses: 5 days
    • Systemic antihistamines or decongestants: 7 days
    • Systemic corticosteroids or cancer chemotherapy, and/or any other systemic medications which the investigator feels may confound study data, or interfere with subject's study participation: 14 days
  5. Have prior (within 7 days of beginning investigational drug) or currently active significant illness that could compromise participation, in the opinion of the investigator;
  6. Have prior (within 30 days of beginning investigational drug) or anticipated concurrent use of an investigational drug or device during the study period;
  7. Have an ocular or systemic condition or a situation which, in the investigator's opinion, may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation;
  8. Have planned surgery (ocular or systemic) during the trial period or within 30 days after the study period;
  9. Be currently breast feeding or planning to breast feed during the study period or is a female who is currently pregnant, is planning a pregnancy, or has a positive urine pregnancy test at Visit 1;
  10. Have a diagnosis of ocular hypertension or glaucoma at screening;
  11. Have symptoms that, in the opinion of the investigator, may be associated with COVID-19 or in the last 14 days came into contact with someone diagnosed with COVID-19.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
380 participants (actual)

Study arms

  • Experimental
    Brimonidine tartrate preservation-free

    Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation

    Drug: Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation

  • Active comparator
    Lumify®

    Lumify® (brimonidine tartrate ophthalmic solution 0.025%)

    Drug: Lumify® (brimonidine tartrate ophthalmic solution 0.025%)

Interventions

06

What researchers measure

Primary outcomes

  1. Ocular Redness

    Ocular redness score evaluated by the investigator from 5 minutes to 240 minutes after investigational drug instillation (0-4 unit scale, where 0 = None and 4 = Extremely severe).

    Time frame: Assessed at 5, 15, 30, 60, 90,120,180, 240 minutes post instillation.

07

Results

Posted Aug 26, 2024

Participant flow

Participant flow — Overall Study
MilestoneBrimonidine Tartrate Preservation-freeLumify®
Started190190
Completed165179
Not completed2511
Withdrew: Discontinued2511

Outcome measures

PrimaryOcular Redness

Ocular redness score evaluated by the investigator from 5 minutes to 240 minutes after investigational drug instillation (0-4 unit scale, where 0 = None and 4 = Extremely severe).

Time frame:
Assessed at 5, 15, 30, 60, 90,120,180, 240 minutes post instillation.
Reported as:
Mean · score on a scale
Ocular Redness
score on a scaleBrimonidine Tartrate Preservation-freeLumify®
5 minutes Post Instillation0.46 ± 0.0390.53 ± 0.041
15 minutes Post Instillation0.40 ± 0.0380.49 ± 0.041
30 minutes Post Instillation0.42 ± 0.0380.50 ± 0.041
60 minutes Post Instillation0.47 ± 0.0400.52 ± 0.041
90 minutes Post Instillation0.54 ± 0.0430.58 ± 0.044
120 minutes Post Instillation0.64 ± 0.0460.67 ± 0.046
180 minutes Post Instillation0.79 ± 0.0460.84 ± 0.049
240 minutes Post Instillation0.99 ± 0.0470.98 ± 0.049

Adverse events

Collected over Through study completion, an average of 36 days.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brimonidine Tartrate Preservation-free0/188 (0%)0/188 (0%)13/188 (6.9%)
Lumify®0/190 (0%)1/190 (0.5%)18/190 (9.5%)
Most frequent serious events
Most frequent serious events
EventBrimonidine Tartrate Preservation-freeLumify®
SepsisInfections and infestations0/1881/190
Most frequent other events
Most frequent other events
EventBrimonidine Tartrate Preservation-freeLumify®
Instillation site painGeneral disorders6/1886/190
SinusitisInfections and infestations2/1886/190
Covid 19Infections and infestations5/1882/190
Visual acuity reducedEye disorders0/1884/190

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Brimonidine Tartrate Preservation-freeLumify®Total
<=18 years000
Between 18 and 65 years114106220
>=65 years7684160
Age, Continuous
Age, Continuous(years)Brimonidine Tartrate Preservation-freeLumify®Total
Mean58.4 ± 14.6559.5 ± 14.7659 ± 14.70
Sex: Female, Male
Sex: Female, Male(Participants)Brimonidine Tartrate Preservation-freeLumify®Total
Female142125267
Male4865113
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Brimonidine Tartrate Preservation-freeLumify®Total
Hispanic or Latino121729
Not Hispanic or Latino178173351
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Brimonidine Tartrate Preservation-freeLumify®Total
American Indian or Alaska Native145
Asian235
Native Hawaiian or Other Pacific Islander000
Black or African American464389
White138138276
More than one race314
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(Participants)Brimonidine Tartrate Preservation-freeLumify®Total
United States190190380
08

Study locations

6 sites
  • Bausch Site 04
    Colorado Springs, Colorado 80907, United States
  • Bausch Site 05
    Louisville, Kentucky 40206, United States
  • Bausch Site 01
    Andover, Massachusetts 01810, United States
  • Bausch Site 03
    Shelby, North Carolina 28150, United States
  • Bausch Site 02
    Memphis, Tennessee 33119, United States
  • Bausch Site 06
    Clinton, Utah 84015, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Nov 2022, 6 months.

Results were first posted in Aug 2024, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2022
First posted
May 4, 2022
StartActual
May 13, 2022
Primary completionActual
Nov 23, 2022
CompletionActual
Nov 23, 2022
Results first posted
Aug 26, 2024
Last update
Aug 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05360784
Responsible party
Sponsor
First posted
May 4, 2022
Start date
May 13, 2022
Primary completion
Nov 23, 2022
Completion
Nov 23, 2022
Results posted
Aug 26, 2024
Last update
Aug 26, 2024

Study contacts

Daniel Donatello
study director · Bausch & Lomb Incorporated

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion